Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
177Lu-labeled DOTA-EB-RGD as a candidate for thyroid cancer therapy
Sonam Kumari, Rhitajit Sarkar, Zhantong Wang, Shilpa Thakur, Laura Abaandou, Oksana Gavrilova, Huiyan Lu, Noha Behairy, Lixin Lang, Dale Kiesewetter, Vasyl Vasko, Joanna Klubo-Gwiezdzinska
Sonam Kumari, Rhitajit Sarkar, Zhantong Wang, Shilpa Thakur, Laura Abaandou, Oksana Gavrilova, Huiyan Lu, Noha Behairy, Lixin Lang, Dale Kiesewetter, Vasyl Vasko, Joanna Klubo-Gwiezdzinska
View: Text | PDF
Research Article Endocrinology Oncology

177Lu-labeled DOTA-EB-RGD as a candidate for thyroid cancer therapy

  • Text
  • PDF
Abstract

Integrin αVβ3, a transmembrane receptor involved in tumor growth and metastasis, specifically recognizes and binds proteins with the Arg-Gly-Asp (RGD) peptide sequence. Using mRNA and/or protein expression data from 496 thyroid cancer (TC) samples in The Cancer Genome Atlas, 14 TC cell lines, and 70 TC and 10 normal thyroid tissues, we found that papillary TC exhibits the highest αVβ3 integrin expression. We then evaluated the therapeutic efficacy of a radiolabeled RGD analog, 177Lu-DOTA-EB-cRGDfK, in TC. Genetic knockout and overexpression of αVβ3 in TC cell lines confirmed the target specificity of 177Lu-DOTA-EB-cRGDfK. In mouse xenograft models established from human TC cell lines with high αVβ3 expression, 177Lu-DOTA-EB-cRGDfK demonstrated superior antitumor efficacy compared with standard-of-care lenvatinib and placebo. However, no synergistic benefit was observed with combination therapy. Biodistribution studies identified the kidneys as the dose-limiting organ. RNA-seq analysis of resected tumors demonstrated that 177Lu-DOTA-EB-cRGDfK induced a type I IFN response, characterized by upregulation of IFI6, IFIT1-2, and MX1, compared with both lenvatinib-treated tumors and placebo. These findings identify αVβ3 integrin as a promising therapeutic target in a subset of TCs and demonstrate that 177Lu-DOTA-EB-cRGDfK exhibits superior efficacy to lenvatinib, supporting its potential clinical translation for progressive TC refractory to standard therapies.

Authors

Sonam Kumari, Rhitajit Sarkar, Zhantong Wang, Shilpa Thakur, Laura Abaandou, Oksana Gavrilova, Huiyan Lu, Noha Behairy, Lixin Lang, Dale Kiesewetter, Vasyl Vasko, Joanna Klubo-Gwiezdzinska

×

Figure 5

177Lu-DOTA-EB-RGD treatment in subcutaneous TC tumor models.

Options: View larger image (or click on image) Download as PowerPoint

177Lu-DOTA-EB-RGD treatment in subcutaneous TC tumor models.
(A) Tumor ...
(A) Tumor growth velocity analysis by 2-way mixed-effects model ANOVA revealed that treatment with 177Lu-DOTA-EB-RGD (177Lu) led to significant tumor growth reduction over time compared with placebo (P < 0.001) and lenvatinib alone (P < 0.001). Combination therapy (177Lu+L) decreased tumor growth compared with lenvatinib monotherapy (P < 0.001), although having similar effect as 177Lu monotherapy (P = 0.79). (B) Representative PET scan images depicting uptake of 68Ga-DOTA-RGD2 in tumors showing significantly lower uptake in mice exposed to combination therapy (177Lu+L, SUVmax 0.75 ± 0.11) in comparison with the placebo group (SUVmax 1.12 ± 0.11; P = 0.001) as well as lenvatinib (0.98 ± 0.21; P = 0.045) (1-way ANOVA with Holm-Šídák multiple-comparison test). (C) Resected tumors collected from each group show that treatment with 177Lu in monotherapy or combination therapy led to a significant reduction of tumor volume (median [IQR], 2-way mixed-effects model ANOVA) with respect to placebo [P] (177Lu 0.350 cm3 [0.172–0.508] vs. P 0.928 cm3 [0.196–1.674], P = 0.0001; and 177Lu+L 0.310 cm3 [0.214–0.335] vs. P 0.928 cm3 [0.196–1.674], P < 0.0001). The combination therapy (177Lu+L, 0.337 cm3) resulted in decreased tumor volume as compared with monotherapy with lenvatinib (0.855 cm3, P = 0.05) but had a similar effect as compared with 177Lu monotherapy (P = 0.99). (D) No treatment-associated difference in 68Ga-DOTA-RGD distribution at the conclusion of the experiment in normal organs other than from higher variability in heart exposure in 177Lu monotherapy as compared with placebo (2-way ANOVA). (E) Ex vivo biodistribution studies in 177Lu monotherapy and 177Lu +L revealed that the kidneys had a similar radiation exposure to the tumors, while exposure to the heart and liver was significantly lower (2-way ANOVA). The number of mice (n) studied for each group was: placebo, n = 8; lenvatinib, L, n = 7; 177Lu, n = 8; 177Lu+L, n = 6. **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts